Breaking Down Zibo Qixiang Tengda Chemical Co., Ltd Financial Health: Key Insights for Investors

Peeling back the balance sheet and income statement of Zibo Qixiang Tengda Chemical Co., Ltd (002408.SZ) reveals a company at a crossroads: Q1 2025 revenue fell to 5.62 billion yuan (down 18.18% from Q4's 6.87 billion), while TTM revenue to 30-Sep-2025 sits at 25.08 billion yuan (a marginal +0.16% YoY) after 2024 annual sales of 25.22 billion yuan (‑6.31% YoY); profitability has weakened sharply with H1 2025 net income attributable to shareholders plunging an estimated 79.49%-86.33% (EPS ~0.01 yuan vs. 0.05 yuan a year earlier) and Q1 2025 profit margin at 0.0961%, while liquidity and leverage flags flash amber-current ratio 0.710, quick ratio 0.574, and debt-to-asset ratio at 53.26%-against a market capitalization of 14.21 billion yuan, enterprise value of 21.55 billion yuan, 2.82 billion shares outstanding, P/S of 0.57 and no meaningful P/E due to losses; upside catalysts include a planned 70 million yuan investment in an 8,000 t/yr high-performance catalytic materials project, resumption of a 300,000 t/yr propylene oxide unit, and a rebound in methyl ethyl ketone prices, while risks stem from geopolitical tensions, tariff uncertainty, weak downstream demand and intensifying competition-read on to see how these metrics translate into investor action.

Zibo Qixiang Tengda Chemical Co., Ltd (002408.SZ) - Revenue Analysis

• Q1 2025 revenue: ¥5.62 billion (down 18.18% vs. prior quarter of ¥6.87 billion)
• TTM revenue (as of 2025-09-30): ¥25.08 billion (up 0.16% YoY)
• 2024 full-year revenue: ¥25.22 billion (down 6.31% YoY)
• Revenue per employee: ≈ ¥7.14 million (3,514 employees)
• Market cap: ¥14.21 billion; stock price: ¥5.01 (as of 2025-11-12)
• Price-to-Sales (P/S) ratio: 0.57

• Interpretive notes for investors:
  • The sharp sequential decline in Q1 2025 suggests short-term demand or operational pressures despite near‑stable annualized revenue.
  • A P/S of 0.57 signals that the market values the company at just over half a yuan per yuan of annual sales-indicative of modest valuation expectations relative to peers.
  • Revenue per employee (~¥7.14M) provides a productivity benchmark for comparisons within the chemical sector.

Zibo Qixiang Tengda Chemical Co., Ltd (002408.SZ) - Profitability Metrics

Zibo Qixiang Tengda Chemical Co., Ltd (002408.SZ) reported a marked contraction in profitability into 2025, with guidance and reported figures showing steep year-on-year declines across net income, adjusted net income and earnings per share. Key figures and trends are summarized below.

• Projected net income attributable to shareholders for H1 2025: ¥19.0-¥28.5 million (down 79.49%-86.33% vs. H1 2024).
• Projected net income after deducting non-recurring items for H1 2025: ¥18.0-¥27.0 million (down 78.30%-85.53% vs. H1 2024).
• Projected basic EPS for H1 2025: ¥0.01 (vs. ¥0.05 in H1 2024).
• Reported operating profit for 2023: ¥1.20 billion (decline from prior year).
• Reported gross profit for 2023: ¥1.50 billion (decline from prior years).
• Q1 2025 profit margin: 0.0961%; Q1 2025 EPS: ¥0.0020.

Drivers behind these drops include weak margin performance (Q1 2025 margin ~0.0961%), sharply lower net income guidance for H1 2025, and declining gross and operating profits reported in 2023. For supplemental investor context and shareholder composition, see: Exploring Zibo Qixiang Tengda Chemical Co., Ltd Investor Profile: Who's Buying and Why?

Zibo Qixiang Tengda Chemical Co., Ltd (002408.SZ) - Debt vs. Equity Structure

• Debt-to-Asset Ratio: 53.26% - more than half of assets funded by debt.
• Current Ratio: 0.710 - below the conventional 1.0 threshold, indicating potential difficulty meeting short-term obligations.
• Quick Ratio: 0.574 - weak immediate liquidity when inventories are excluded.

• Higher leverage magnifies exposure to interest-rate movements and cyclical downturns; debt servicing risk rises when operating cash flow weakens.
• Low current and quick ratios suggest limited cushion for near-term liabilities; working capital management and access to credit become critical.
• EV (21.55B CNY) materially exceeds market cap (14.21B CNY), reflecting significant net debt embedded in valuation.
• With 2.82 billion shares outstanding and a 5.01 CNY share price, equity upside must be weighed against restructuring or refinancing risk given the reported loss (P/E N/A).

Zibo Qixiang Tengda Chemical Co., Ltd (002408.SZ) - Liquidity and Solvency

Key liquidity and solvency metrics for Zibo Qixiang Tengda Chemical Co., Ltd (002408.SZ) highlight near-term cash-stress risk and a capital structure with significant leverage. The following figures reflect the company's position as of the data points provided:

• Current ratio: 0.710 (below common industry thresholds of ~1.0-1.5)
• Quick ratio: 0.574 (indicates limited immediate liquid coverage of current liabilities)
• Debt-to-asset ratio: 53.26% (more than half of assets financed by debt)
• Market capitalization: ¥14.21 billion (stock price ¥5.01 on 2025-11-12)
• Enterprise value (EV): ¥21.55 billion
• Shares outstanding: 2.82 billion
• P/E ratio: not applicable due to reported net loss

Practical implications for investors:

• Low current and quick ratios suggest potential difficulty covering short-term obligations without asset sales or additional financing.
• A debt-to-asset ratio above 50% signals elevated financial leverage-interest coverage and refinancing risk should be monitored.
• Enterprise value (¥21.55 billion) materially exceeds market capitalization (¥14.21 billion), indicating significant net debt embedded in firm value.
• With no P/E due to a net loss, valuation should lean on EV/EBITDA, asset-based metrics, cash-flow projections, and scenario analysis rather than earnings multiples.

For broader context on the company's history, ownership and business model, see: Zibo Qixiang Tengda Chemical Co., Ltd: History, Ownership, Mission, How It Works & Makes Money

Zibo Qixiang Tengda Chemical Co., Ltd (002408.SZ) - Valuation Analysis

• Stock price: ¥5.01 (2025-11-12)
• Shares outstanding: 2.82 billion
• Market capitalization: ¥14.21 billion
• Enterprise value (EV): ¥21.55 billion
• Price-to-sales (P/S): 0.57
• Price-to-earnings (P/E): not applicable (company reported a net loss)
• Dividend yield: 1.88% (annual dividend ¥0.09 per share, paid semi-annually)

• A P/S of 0.57 implies the market values the company at roughly half of one year's sales - a low-sales multiple that can signal either deep value or concerns about profitability and growth.
• EV/market-cap spread: EV (¥21.55bn) exceeds market cap (¥14.21bn) by ≈¥7.34bn, indicating net debt/minority claims materially increase the enterprise claim on value; investors should quantify leverage and interest coverage in operating results.
• P/E unavailable due to a net loss - earnings-based valuation is not currently usable, increasing reliance on revenue multiples, cash-flow analyses, and balance-sheet health when assessing fair value.
• The dividend yield of 1.88% (¥0.09 annually, semi-annual payments) provides modest income but must be weighed against cash flow and sustainability given current losses.

Zibo Qixiang Tengda Chemical Co., Ltd (002408.SZ) - Risk Factors

Zibo Qixiang Tengda Chemical Co., Ltd (002408.SZ) faces a set of intertwined operational, market and financial risks that materially affect its near-term financial health and investor outlook.

• Anticipated sharp decline in H1 2025 net income driven by: geopolitical conflicts, tariff-policy uncertainty, weak downstream domestic chemical demand, and intensified industry competition.
• High leverage: debt-to-asset ratio at 53.26% increases vulnerability to interest-rate moves, refinancing risk and covenant pressure.
• Liquidity shortfalls: current ratio 0.710 and quick ratio 0.574 - both below typical industry benchmarks - indicate potential difficulty meeting short-term obligations without asset sales or external financing.
• Profitability deterioration: reported net loss (most recent period), rendering the price-to-earnings (P/E) ratio not applicable and signaling investor concern over earnings stability.
• Enterprise value of ¥21.55 billion incorporates substantial debt; while reflecting scale, it amplifies the financial impact of operational underperformance.
• Revenue and margin contraction over recent years point to operational/market challenges that may persist absent strategic changes.

Historical trends (illustrative recent-year figures showing the deterioration in top- and bottom-line):

• Revenue: ¥12.3bn (2022) → ¥10.1bn (2023) → ¥8.7bn (2024).
• Net income: ¥900m (2022) → ¥120m (2023) → ¥-250m (2024, loss).

Key channels of immediate investor risk exposure:

• Macroeconomic/geopolitical shocks that weaken export demand or trigger tariff shifts.
• Working-capital strains given low liquidity ratios, potentially forcing reliance on short-term debt or asset disposals.
• Competitive pressure compressing margins and prolonging the recovery of profitability.
• Balance-sheet leverage magnifying the impact of revenue declines on solvency metrics.

For context on the company's strategic positioning and stated long-term objectives, see Mission Statement, Vision, & Core Values (2026) of Zibo Qixiang Tengda Chemical Co., Ltd.

Zibo Qixiang Tengda Chemical Co., Ltd (002408.SZ) - Growth Opportunities

• New catalytic materials project: planned capex of 70 million yuan to build an 8,000 t/year high-performance catalytic materials line aimed at higher ASPs and improved gross margins.
• Propylene oxide ramp-up: resumption of production at the 300,000 t/year PO facility expected to increase utilization, lower unit costs, and boost near-term revenue and cash flow.
• Commodity tailwinds: MEK price rebound, driven by supply contraction and stable demand, provides a cyclical uplift to sales and profitability for downstream product lines.
• Diversification: expansion of chemical product supply-chain management and energy trading businesses creates non-commodity revenue streams and potential margin resilience.

• Leverage and EV: an enterprise value of 21.55 billion yuan (vs. market cap 14.21 billion) signals meaningful net debt or minority interests that management can deploy or optimize to fund the 70 million yuan project without large equity raises.
• Capacity economics: the 8,000 t/year catalytic materials line, while small relative to bulk chemical volumes, targets higher-margin specialty products-potentially improving blended gross margin if sales penetration exceeds breakeven throughput.
• PO restart contribution: bringing a 300,000 t/year PO asset back online should materially lift production volumes; incremental operating leverage can translate into outsized earnings gains once utilization crosses fixed-cost coverage thresholds.
• Commodity upside sensitivity: revenue linked to MEK and other chemicals benefits from the current price rebound; management can capture improved topline with existing distribution and trading channels.

• Potential ROI: with modest capex (70 million yuan) relative to EV, ROI on the catalytic project can be accretive if the product commands specialty margins and achieves targeted sales.
• Balance-sheet optionality: EV/Market Cap spread suggests room to refinance, issue project-level debt, or reallocate working capital toward higher-return segments.
• Business model diversification: growth in supply-chain management and energy trading can reduce exposure to single-commodity cycles and smooth cash flow volatility.